The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

David Spigel, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.

September 2, 2015

Changing the Way Takeda Oncology Develops Cancer Medicines

Dixie-Lee Esseltine, MD and George Mulligan, PhD offer insight on the impact of ixazomib on Takeda Oncology’s approach to multiple myeloma care and its approach to other cancer types.

March 31, 2015

Beginnings of Personalized Medicine for Myeloma

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.